N4P '' A little known story ''

By James Moore


Today I had a chat with Nigel Theabold CEO of N4 Pharma, the small private company hit the headlines when Aim listed investment company Onzima Ventures announced its investment for 49% of the company. The business works extensively on a number of compounds through the early development stage, with a novel structure which reduces significant dilution whilst focusing on progressing quickly into presenting its products through its technology platform.

  • Business model to reformulate and develop erectile dysfunction drugs

  • Strong background in product development working with Oxford Pharma Science

  • New clinical and commercial products into the forefront of industry

  • Regular focus on news flow with as the exciting outlook surfaces further


Author: James Moore

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

Sign up for Investing Intel Newsletter